European Journal of Cancer
Volume 42, Issue 5 , Pages 598-607, March 2006

High-throughput techniques in breast cancer: A clinical perspective

“Service of Medical Oncology”, Hospital La Paz – Universidad Autónoma, Paseo de la Castellana, 261, 28046 Madrid, Spain

Received 10 June 2005; accepted 22 November 2005.

Abstract 

High-throughput technologies such as DNA-microarrays, RT-PCR and proteomics can improve the prognostic and predictive information acquired from classical parameters. Unlike information gathered by classical methods, high-throughput technologies can accurately inform clinicians on patient response to adjuvant therapy or those who will resist the effect of that therapy. Studies performed in breast cancer with high-throughput techniques have focused on tumour biology, prognosis, prediction of response to a few agents and, more recently, early diagnosis. However, further refinement is needed before these techniques become part of clinical routine. In the meantime, they will be used in clinical investigation, particularly in the areas of hormonal therapy and adjuvant chemotherapy, where modest improvements in the capacity of prediction can benefit many women. Close cooperation among clinicians, pathologists and basic investigators is essential to take high-throughput techniques to daily practice. New diagnostic tools will be complex but they will provide valuable patient information.

Keywords: Breast cancer, Clinical trials, DNA microarrays, PCR, Treatment outcome, Prognosis, Proteomics, Review

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(05)01076-2

doi:10.1016/j.ejca.2005.11.021

European Journal of Cancer
Volume 42, Issue 5 , Pages 598-607, March 2006